argenex (NASDAQ:ARGX) Upgraded at Wall Street Zen

argenex (NASDAQ:ARGX) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other analysts have also commented on the company. Royal Bank Of Canada lifted their price target on argenex from $945.00 to $1,025.00 and gave the company an “outperform” rating in a research report on Friday. Citizens Jmp lowered their price objective on argenex from $944.00 to $932.00 and set a “market outperform” rating on the stock in a research report on Friday. Weiss Ratings cut shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Morgan Stanley lifted their target price on shares of argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Finally, Bank of America boosted their target price on shares of argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,050.50.

argenex Stock Performance

NASDAQ:ARGX opened at $918.22 on Friday. The firm’s fifty day moving average is $868.28 and its two-hundred day moving average is $815.12. The firm has a market cap of $57.44 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 1.14 and a beta of 0.45. argenex has a one year low of $587.37 and a one year high of $953.58.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating analysts’ consensus estimates of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 70.27% and a net margin of 32.19%. As a group, equities research analysts predict that argenex will post 26.27 earnings per share for the current fiscal year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently modified their holdings of ARGX. Janus Henderson Group PLC grew its position in shares of argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after purchasing an additional 83,568 shares in the last quarter. M&T Bank Corp lifted its position in argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after buying an additional 774,916 shares in the last quarter. Wellington Management Group LLP lifted its position in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares in the last quarter. Morgan Stanley boosted its stake in argenex by 19.2% during the fourth quarter. Morgan Stanley now owns 518,852 shares of the company’s stock worth $436,331,000 after buying an additional 83,746 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in argenex by 390.4% during the fourth quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock worth $350,178,000 after buying an additional 331,489 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Key Stories Impacting argenex

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenex reported Q2 EPS of $7.32, topping estimates, on revenue of $1.54 billion versus expectations of $1.45 billion, highlighting strong operating momentum and profitability. Q2 earnings report and conference call
• Positive Sentiment: Reuters reported that global sales of Vyvgart jumped in the second quarter, a key driver for argenex’s growth and a major reason the stock has been gaining investor attention. Reuters article on Vyvgart sales
• Positive Sentiment: Oppenheimer, RBC, and Guggenheim all raised price targets and maintained bullish ratings, signaling increased Street confidence in argenex’s growth trajectory and pipeline prospects.
• Positive Sentiment: A Seeking Alpha note highlighted surging profitability, robust cash generation, and operational leverage, while pointing to pipeline catalysts such as empasiprubart as additional upside potential. Seeking Alpha rating upgrade article
• Neutral Sentiment: Short-interest data showed 0 shares reported, which provides little actionable signal for investors because the figures appear unchanged and unusually low.
• Negative Sentiment: Citizens JMP trimmed its price target slightly from $944 to $932, though it still kept a positive rating, making this more of a minor caution than a bearish call.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.